Monsanto – Bayer – Germany


In September 2018, the company reported low earnings for the second quarter of 2018. The sharp income drop follows the German firm’s acquisition of US-based crop science giant Monsanto.    Bayer paid €54 billion ($61.4 billion) which was the biggest foreign takeover in history for a German firm.
Perhaps George Soros, the Gates their families, the board of directors of Bayer could each drink a Litre  of glyphosate for 2 years on a daily basis,  to show the world it is safe.

Bayer AG Logo (picture-alliance/Geisler/C. Hardt)



The Gates and Soros can enjoy each other on worldwide tv and drink glasses of Glyphosate themselves for 2 years?
Alles gaan oor mag en beheer en om die bevolking te verminder.   Grootskaalse mediese uitgawes gee aanleiding tot hul ander maatskappye wat gekoppel is aan “medikasie”.
George Soros – SA – Monsanto

Monsanto – George Soros – Suid-Afrika


Bayer – Monsanto – Seed (global)


Rain-Snowstorms in America – Agriculture disaster – Declaration


Monsanto Now Belongs to Bayer   (GERMANY)

In the year’s biggest deal so far, German pharma giant Bayer has bought Monsanto.

Update (9/14/2016): Monsanto has agreed to be sold to Bayer for $56.5 billion—a deal worth a total of $66 billion when Monsanto’s debt is taken into account. Bayer agreed to pay Monsanto a break-up fee of $2 billion if antitrust regulators reject the deal. The combined company would be the globe’s largest seller of both seeds and agrichemicals. It plans to locate its seeds and GM traits division in Monsanto’s home city of St. Louis; its pesticide division will be in Bayer’s home city, Monheim, Germany. No word yet on whether the Monsanto brand will continue to exist.

ALSO – 2018 – The management of the Leverkusen-based Bayer is preparing to strike off 12,000 people between now and the end of 2021, with German employees expected to bear a “significant part” of job losses, the company said.   The multi-national concern is also planning a sale of its animal health unit. Additionally, the company is intent on dropping over-the-counter brands such as Coppertone sun lotion and Dr. Scholl’s foot care products.


US citizen Dewayne Johnson claims exposure to glyphosate, the key ingredient in the Roundup weed killer made by Monsanto, caused his deadly cancer. As groundskeeper for the school district in Benicia, California, Johnson handled hundreds of gallons of Roundup and was diagnosed with cancer in 2014. He was given six months to live.

German chemical giant Bayer’s $63 billion purchase of US firm Monsanto is the largest ever by a German of a non-German company. But Bayer also takes on Monsanto’s problems, which the trial of Dewayne Johnson highlights.

Glyphosate was approved for use in Monsanto’s weed killer in 1974 and later became the world’s most popular herbicide. The question of whether it causes cancer has long been debated by environmentalists, regulators, researchers and lawyers. 

“We need to show that Monsanto knew that their remedy was carcinogenic and they tried to manipulate science,” said Michael Baum, senior partner at Baum Hedlund Aristei & Goldman. He refers to a ruling by the World Health Organization (WHO) and its cancer research agency, which classifies glyphosate as “probably carcinogenic.”

A year after Germany’s Bayer Group took over Monsanto, and it’s struggling to deal with the US seed giant’s controversial reputation. Now Bayer is also liable for Monsanto’s legal bills – which are starting to mount alarmingly. Roundup, a herbicide containing glyphosate sold worldwide by Monsanto has long been suspected of causing cancer. A California court has just awarded more than $2 billion in damages to a couple who had claimed that their use of the pesticide caused them to develop non-Hodgkin’s lymphoma . Bayer’s share price halved last year, and the consequences are already making themselves felt in the company itself: Around 12,000 jobs worldwide are to be cut in the next few years, a considerable proportion of them in Germany. CEO Werner Baumann, who pushed for the merger, is coming under increasing pressure. Voicing criticism, a majority of shareholders voted against absolving Baumann and other managers of their responsibility in the merger. Bayer is in the midst of its greatest crisis. The film traces the effects of the merger and investigates potential new health hazards emanating from glyphosate. How has Monsanto tried in the past to influence politicians, scientists and public opinion? Did the Americans actually play down or ignore the dangers? And does Bayer really distance itself from these practices?


But unforeseeable consequences

“The legal risk of Bayer has increased with the acquisition of Monsanto,” Oxgaard said, adding that the worrying element for Bayer is that the financial consequences are not foreseeable.

The number of litigations against the Leverkusen-based company has, some believe, reached a worrying level. The company is currently facing more than 43,000 complaints, almost twofold as many as at the beginning of 2017. Bayer had to spend some €258 million on legal cases in 2017 and has had to build up a large legal team in the US of 180 employees.

Before the take-over Monsanto had a reserve fund for environmental and litigation liability of $277 million, while Bayer’s provisions for litigation at the end of 2017 were €393 million.    Bayer already paid out $2.1 billion to close 10,600 settlements over its contraceptive pill Yasmin, which was blamed for causing thrombosis. In addition, the company is undergoing MDL (multi-district litigation) with its drug Xarelto — the anticoagulant is accused of serious side effects, with 23,000 patients filing lawsuits.

Bayer goes to market

If the bond market tells us anything about the all-important realm of consumer and investor perception, this week sees the second largest corporate bond sale of the year in the US, with Bayer raising $15 billion (€13.5 billion) in dollar debt and a euro deal worth up to €5 billion. Indicators suggest demand for the bonds is strong.

The combined €18.5 billion will go to pay off some of the leveraged loan for the takeover of Monsanto.

Bottles of Roundup herbicide, a product of Monsanto


Shares of Merck are climbing on Tuesday after German drug-maker Bayer said it would buy its consumer care business for $14.2 billion. The deal is set to make Bayer the second-biggest over-the-counter drug maker behind Johnson & Johnson. Bayer said it should add $2.2 billion in annual sales to its non-prescription business, while Merck said it expects after-tax proceeds of between $8 billion and $9 billion from the deal. It is the latest in a string of M&A activity within the drug sector.

2 gedagtes oor “Monsanto – Bayer – Germany”

Laat 'n boodskap

Verskaf jou besonderhede hieronder of klik op 'n logo om in te teken: Logo

Jy lewer kommentaar met jou rekening by Log Out /  Verander )

Google photo

Jy lewer kommentaar met jou rekening by Google. Log Out /  Verander )

Twitter picture

Jy lewer kommentaar met jou rekening by Twitter. Log Out /  Verander )

Facebook photo

Jy lewer kommentaar met jou rekening by Facebook. Log Out /  Verander )

Connecting to %s